Background: Severe hyper- and hyponatraemia is associated with significant risks, yet its correction can also have serious consequences when implemented too fast or inadequately. The safe correction of serum sodium levels is particularly challenging when renal replacement therapy (RRT) is required. Methods: Using 2 case scenarios, we aim to illustrate a simple method of correcting hyper- and hyponatraemia safely by step-wise manipulation of the dialysate/replacement fluid. Results: During continuous RRT, hypernatraemia can be corrected effectively and safely by adding small pre-calculated amounts of 30% NaCl to the dialysate/replacement fluid bags aiming for a [Na+] in the fluid that allows safe equilibration and correction of the serum [Na+]. To correct hyponatraemia safely, pre-calculated amounts of sterile water can be added in a step-wise manner to achieve a fluid [Na+] that equals the desired target serum [Na+]. Conclusion: During continuous RRT, the step-wise adjustment of [Na+] of dialysate/replacement fluids offers a safe and reliable method to correct sodium disorders.

Bagshaw SM, Townsend DR, McDermid RC: Disorders of sodium and water balance in hospitalized patients. Can J Anesth 2009;56:151-167.
Adrogué HJ, Madias NE: The challenge of hyponatremia. J Am Soc Nephrol 2012;23:1140-1148.
Adrogué HJ, Madias NE: Hypernatremia. N Engl J Med 2000;342:1493-1499.
Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ: Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126(suppl 1):S1-S42.
Ostermann M, Dickie H, Tovey L, Treacher D: Management of sodium disorders during continuous haemofiltration. Crit Care 2010;14:418-419.
Hoorn EJ, Betjes MGH, Weigel J, Zietse R: Hypernatraemia in critically ill patients: too little water and too much salt. Nephrol Dial Transplant 2008;23:1562-1568.
Overgaard-Steensen C, Ring T: Clinical review: practical approach to hyponatraemia and hypernatraemia in critically ill patients. Crit Care 2013;17:206-219.
Sterns RH, Hix JK, Silver SM: Management of hyponatremia in the ICU. Chest 2013;144:672-679.
Asadollahi K, Beeching N, Gill G: Hyponatraemia as a risk factor for hospital mortality. Q J Med 2006;99:877-880.
Adrogué HJ, Madias NE: Hyponatraemia. N Engl J Med 2000;342:1581-1589.
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn E, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E: Clinical practice guideline on diagnosis and treatment of hyponatraemia. Intensive Care Med 2014;40:320-331.
Laureno R, Karp BI: Myelinolysis after correction of hyponatremia. Ann Intern Med 1997;126:57-62.
Morard I, Gasche Y, Kneteman M, Toso C, Mentha A, Meeberg G, Mentha G, Kneteman N, Giostra E: Identifying risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a case-control study. Neurocrit Care 2014;20:287-295.
Vassallo D, Camilleri D, Moxham V, Ostermann M: Successful management of severe hyponatraemia during continuous renal replacement therapy. Clin Kidney J 2012;5:155-157.
Wendland EM, Kaplan AA: A proposed approach to the dialysis prescription in severely hyponatremic patients with end-stage renal disease. Semin Dial 2012;25:82-85.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.